- Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
- 12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated IDeate-Lung02 phase 3 study
Reported Saturday, Daiichi Sankyo And Merck's Ifinatamab Deruxtecan Shows Response Rates In Extensive-Stage Small Cell Lung Cancer In Phase 2 IDeate-Lung01 Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated